학술논문
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
Document Type
Article
Author
Source
In: Journal of Allergy and Clinical Immunology . (Journal of Allergy and Clinical Immunology, December 2022, 150(6):1498-1506.e2)
Subject
Language
English
ISSN
10976825
00916749
00916749